Kenvue Debt Swap Stalls at 74% Tendered, Extended Nov 2
Kimberly-Clark extended its deadline to swap up to $7 billion in Kenvue notes after only 73.93% of the 2028 series tendered by October 27. The equity has priced in the deal at $19.43 against a $19.50
KMB Extends Kenvue Debt Swap; 2028 Notes 74% Tendered
NEW YORK, October 28 —
The equity market in Kenvue Inc. (KVUE) has already cashed the check: shares trade at $19.43, a hair below the $19.50 analyst consensus target. The bond market is still negotiating. Kimberly-Clark extended its deadline to swap up to $7 billion of Kenvue notes after only 73.93% of the 2028 series had tendered by October 27.
- Kimberly-Clark extended the exchange offer expiration to November 2 after 73.93% of $1B in 2028 Kenvue notes tendered.
- Kenvue carries $8.61B in total debt and $1.91B in trailing free cash flow against $1.11B cash.
- Q2 2026 EPS of $0.31 missed consensus by 2.8%, snapping three straight quarters of double-digit beats.
Debt That Won't Move
The exchange offer's architecture matters: Kimberly-Clark is seeking to absorb up to $7 billion in Kenvue-issued notes by swapping them for its own paper, with the arrangement formalized through a Material Definitive Agreement on October 13. The Senior Notes due 2028, with $1 billion outstanding, are one tranche; roughly one-quarter of that series had not tendered by the October 27 deadline, per the extension announcement. Bondholders deciding whether to accept Kimberly-Clark's credit in place of Kenvue's yield are still doing that math. The extension buys time but confirms the swap is not yet a formality.
The Standalone Case Has Cracks
Kenvue's portfolio spans Tylenol, Benadryl, Zyrtec, Neutrogena, Listerine, and Band-Aid, generating $15.41 billion in trailing revenue and a 58.4% gross margin. But the recent fundamental picture has softened. Q2 2026 EPS of $0.31 missed the consensus by 2.8%, ending a three-quarter streak of double-digit beats, with prior surprises of 7.6%, 22.5%, and 23.1%, per the August 8-K. That miss matters for a stock priced as if the deal is done: 15.7x forward earnings and no visible organic catalyst leaves the standalone bull case thin; check the forward P/E calculator.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| KVUE | $37.3B | 15.7x | +33.9% |
| KDP | $47.4B | 13.8x | +20.8% |
| AMCR | $21.2B | 10.6x | +10.0% |
| GEHC | $32.3B | 13.1x | -10.4% |
| HLN | $44.3B | 16.3x | +10.5% |
| TFC | $59.3B | 9.9x | +9.5% |
What November 2 Reveals
November 2 is the next concrete checkpoint. If the tender clears a stronger threshold, the equity read is vindicated; if holdouts persist or other series lag, the exchange becomes a live friction story. Kenvue's $8.61 billion debt load, $1.11 billion in cash, and $1.91 billion in trailing free cash flow show the balance sheet Kimberly-Clark is absorbing, and the bondholder math is not abstract. At $19.43 against a $19.50 consensus target, the equity has already priced the upside; the asymmetry runs toward the downside if November 2 delivers another extension. Run the free Kenvue Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What brands does Kenvue own?
Kenvue's portfolio spans Tylenol, Benadryl, Zyrtec, Neutrogena, Listerine, and Band-Aid, generating $15.41 billion in trailing revenue with a 58.4% gross margin. The company's Q2 2026 EPS of $0.31 missed consensus by 2.8%, ending three quarters of double-digit beats.
Why is Kimberly-Clark swapping Kenvue debt?
Kimberly-Clark formalized a Material Definitive Agreement on October 13 to absorb up to $7 billion in Kenvue notes by exchanging them for its own paper. The 5.050% Senior Notes due 2028 represent one tranche of the swap, with $1 billion outstanding.
What does 74% tender rate signal?
Only 73.93% of the 2028 Kenvue notes had tendered by October 27, with roughly one-quarter of that series still not accepted. This signals bondholder hesitation about accepting Kimberly-Clark's credit in place of Kenvue's yield.
What is Kenvue's financial position?
Kenvue carries $8.61 billion in total debt, $1.11 billion in cash, and $1.91 billion in trailing free cash flow. The company trades at 15.7x forward earnings with no visible organic catalyst, leaving the standalone case thin.
What happens November 2?
The new deadline will reveal whether the remaining bondholders accept the swap or holdouts persist. If the tender clears a stronger threshold, the equity read is vindicated; if holdouts remain, the exchange becomes a live friction story with asymmetric downside for shareholders.
Kimberly-Clark extended the deadline on its exchange offers for up to $7 billion of Kenvue debt after only 73.93% of the 2028 notes had tendered by October 27—the same week Kenvue stock trades at $19.43, essentially at its $19.50 analyst consensus target, pricing in deal certainty that the bond market has yet to confirm.